论文部分内容阅读
目的:探讨TOPO-Ⅱ、Ki-67在乳腺癌中的表达及临床意义。方法:收集2011年1月—2014年1月诊治的乳腺癌患者75例临床资料,采用免疫组化检测癌组织TOPO-Ⅱ、Ki-67的表达,并分析其与临床病理参数、组织学分级、临床分期等的相关性。结果:TOPO-Ⅱ在乳腺癌中的阳性表达率为60.0%,Ki-67的阳性表达率为77.3%,TOPO-Ⅱ的阳性表达与患者组织学分级、TNM临床分期、淋巴结转移有关(P<0.05),与患者年龄、肿瘤的大小无关(P>0.05);Ki-67与组织学分级有关(P<0.01),与年龄、肿瘤的大小、TNM临床分期、淋巴结转移均无关(均P>0.05)。结论:TOPO-Ⅱ和Ki-67在乳腺癌中高表达,且均与组织学分级有关,检测两者水平对评估乳腺癌患者的预后和指导临床治疗有重要意义。
Objective: To investigate the expression and clinical significance of TOPO-Ⅱ and Ki-67 in breast cancer. Methods: The clinical data of 75 patients with breast cancer who were diagnosed and treated from January 2011 to January 2014 were collected. The expression of TOPO-Ⅱ and Ki-67 in cancer tissue was detected by immunohistochemistry and analyzed with clinicopathological parameters, histological grade , Clinical stage and other related. Results: The positive expression rate of TOPO-Ⅱ in breast cancer was 60.0% and the positive expression rate of Ki-67 was 77.3%. The positive expression of TOPO-Ⅱ was correlated with histological grade, TNM clinical stage and lymph node metastasis (P < (P <0.05). There was no correlation between Ki-67 and histological grade (P <0.01), and had no correlation with age, tumor size, TNM clinical stage and lymph node metastasis (P> 0.05). CONCLUSION: TOPO-Ⅱ and Ki-67 are highly expressed in breast cancer, and are related to histological grade. The detection of both levels of TOPO-Ⅱ and Ki-67 is of great significance in assessing prognosis and guiding clinical treatment of patients with breast cancer.